Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 183 Print this page  Email this page Small font size Default font size Increase font size
REVIEW ARTICLE
Year : 2016  |  Volume : 31  |  Issue : 2  |  Page : 89-92

Pharmacovigilance in radiopharmaceuticals


1 Pharmacovigilance Division, Indian Pharmacopoeia Commission, National Coordination Centre-Pharmacovigilance Programme of India, India
2 Pharmacovigilance Division, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India

Correspondence Address:
Rishi Kumar
Indian Pharmacopoeia Commission, National Coordination Centre-Pharmacovigilance Programme of India, Ghaziabad, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-3919.178252

Rights and Permissions

Indian Pharmacopoeia Commission is Committed for maintaining the standards of drugs including Radiopharmaceuticals (RPs) by publishing Indian Pharmacopoeia. These RPs are being used in India for diagnostic or therapeutic purpose. RPs though contain relatively small quantities of active ingredient and administered in small volumes could cause some adverse reactions to the patients. The objective of presenting this article is to introduce the system of adverse drug reaction reporting to the nuclear medicine fraternity who are dealing with RPs.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1366    
    Printed11    
    Emailed0    
    PDF Downloaded140    
    Comments [Add]    

Recommend this journal